DOI: https://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20222980
Published: 2022-11-15

Role of intralesional measles, mumps and rubella vaccine in treatment of warts

Noreen Munshi, Krishnendra Varma

Abstract


Background: Objective of the research was to study the efficacy and safety of measles, mumps and rubella (MMR) vaccine in the treatment of warts.

Methods: 53 patients with single or multiple warts in all age groups were included in the study. The patients received intralesional MMR vaccine 0.5ml into a single wart or the largest wart in case of multiple lesions at interval of 3 weeks for 3 treatments. All patients were followed up every 2 months up to 6 months regarding relapses. side effects and therapeutic outcomes were evaluated.

Results: Out of 53 patients, 50 completed the study. Complete response was seen in 36 (72%), partial response in 09 (18%) and no response in 05 (10%) patients. 3 out of 36 patients with complete response were having recurrence of warts. Pain at the site of injection and flu like symptoms were the main side effects observed.

Conclusions: Intralesional immunotherapy with MMR vaccine was found to be a simple, effective, and safe treatment for warts. This study proved to be cost effective as patients can be treated with just 03 doses of MMR vaccine given at the interval of three weeks.


Keywords


Measles mumps and rubella, Vaccine, Warts, Human papilloma virus

Full Text:

PDF

References


Sterling JC, Handfield-Jones S, Hudson PM; British Association of Dermatologists. Guidelines for the management of cutaneous warts. Br J Dermatol. 2001;144:4-11.

Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013;445(1-2):224-31.

Dall'oglio F, D'Amico V, Nasca MR, Micali G. Treatment of cutaneous warts: An evidence-based review. Am J Clin Dermatol. 2012;13:73-96.

Zamanian A, Mobasher P, Jazi GA. Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart. Adv Biomed Res. 2014;3:107.

Zamanian A, Mobasher P, Jazi GA. Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart. Adv Biomed Res. 2014;3:107.

Awal G, Kaur S. Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. J Clin Aesthetic Dermatol. 2018;11(5):15-20.

Shah AN, Patel D, Ravishankar V. Measles, mumps and rubella vaccine as an intralesional immunotherapy in treatment of warts. Int J Res Med Sci. 2016;4:472-6.

Nofal A, Nofal E. Intralesional immunotherapy of common warts: Successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol. 2010;24:1166-70.

Dhope A, Madke B, Singh AL. Effect of measles mumps rubella vaccine in treatment of common warts. Indian J Drugs Dermatol. 2017 3(1):14-9.

Johnson SM, Roberson PK, Horn TD. Intralesional injection of mumps or candida skin test antigens: a novel immunotherapy for warts. Arch Dermatol. 2001;137(4):451-5.

Saini P, Mittal A, Gupta LK, Khare AK, Mehta S. Intralesional mumps, measles and rubella vaccine in the treatment of cutaneous warts. Indian J Dermatol. Venereol Leprol. 2016;82(3):343-5.